Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1. Now, research ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

such as glucagon-like peptide-1, free fatty acids, and catecholamines. With this knowledge, scientists are seeking to better understand the role of GPCRs in islet biology and hormone secretion ...

Take glucagon-like peptide-1 receptor agonists (GLP-1s ... DiMarchi smashed the prevailing view that changing natural human sequence was a "risky proposition more likely to increase toxicity ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

For example, the company is developing an NIPEP-TPP anti-mutant KRAS antibody that binds the G12C mutant form of the human KRAS ... hormone (PTH) or glucagon-like peptide-1 (GLP-1) receptor ...